Table 4.
Annual cost reductions based on 2011 actual utilization of ESA and IV iron as a function of reduction in ESA and IV iron arising from ferric citrate usage
| ESA reduction | IV iron reduction
|
||
|---|---|---|---|
| 0.30 | 0.40 | 0.50 | |
| 0.10 | 0.467 (0.341–0.600) |
0.511 (0.382–0.649) |
0.555 (0.423–0.692) |
| 0.20 | 0.830 (0.584–1.035) |
0.868 (0.632–1.084)a |
0.918 (0.672–1.132) |
| 0.30 | 1.192 (0.831–1.486) |
1.236 (0.869–1.529) |
1.273 (0.915–1.578) |
Notes: Cost reductions are expressed as the median and 20th and 80th percentiles (in billion USD).
a
Most likely result.
Abbreviations: ESA, erythropoietin-stimulating agent; IV, intravenous.